BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 32976510)

  • 21. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice Trends.
    Devereaux KA; Souers RJ; Merker JD; Lindeman NI; Graham RP; Hameed MR; Vasalos P; Moncur JT; Lockwood CM; Xian RR
    Arch Pathol Lab Med; 2023 Apr; 147(4):425-433. PubMed ID: 35687785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal
    Kumaki Y; Olsen S; Suenaga M; Nakagawa T; Uetake H; Ikeda S
    Curr Oncol; 2021 Sep; 28(5):3717-3728. PubMed ID: 34677235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analytic validation of NeXT Dx™, a comprehensive genomic profiling assay.
    Saldivar JS; Harris J; Ayash E; Hong M; Tandon P; Sinha S; Hebron PM; Houghton EE; Thorne K; Goodman LJ; Li C; Marfatia TR; Anderson J; Morra M; Lyle J; Bartha G; Chen R
    Oncotarget; 2023 Aug; 14():789-806. PubMed ID: 37646774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies.
    Fitarelli-Kiehl M; Yu F; Ashtaputre R; Leong KW; Ladas I; Supplee J; Paweletz C; Mitra D; Schoenfeld JD; Parangi S; Makrigiorgos GM
    Clin Chem; 2018 Dec; 64(12):1762-1771. PubMed ID: 30274976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients.
    Macías M; Cañada-Higueras E; Alegre E; Bielsa A; Gracia J; Patiño-García A; Ferrer-Costa R; Sendino T; Andueza MP; Mateos B; Rodríguez J; Corral J; Gúrpide A; Lopez-Picazo JM; Perez-Gracia JL; Gil-Bazo I; Alkorta-Aranburu G; González Á
    Clin Chem Lab Med; 2020 Jul; 58(8):1341-1348. PubMed ID: 32623849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers.
    Rickles-Young M; Tinoco G; Tsuji J; Pollock S; Haynam M; Lefebvre H; Glover K; Owen DH; Collier KA; Ha G; Adalsteinsson VA; Cibulskis C; Lennon NJ; Stover DG
    J Mol Diagn; 2024 May; 26(5):413-422. PubMed ID: 38490303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
    Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
    Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing.
    Herrmann S; Zhan T; Betge J; Rauscher B; Belle S; Gutting T; Schulte N; Jesenofsky R; Härtel N; Gaiser T; Hofheinz RD; Ebert MP; Boutros M
    Mol Oncol; 2019 Aug; 13(8):1669-1683. PubMed ID: 31254442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.
    Leighl NB; Page RD; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA
    Clin Cancer Res; 2019 Aug; 25(15):4691-4700. PubMed ID: 30988079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of Loss of Heterozygosity in cfDNA of Advanced
    Boldrin E; Nardo G; Zulato E; Bonanno L; Polo V; Frega S; Pavan A; Indraccolo S; Saggioro D
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
    Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
    Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
    Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
    Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Comparative Study for Detection of
    Kim Y; Shin S; Lee KA
    Biomed Res Int; 2018; 2018():7392419. PubMed ID: 29854785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discrimination of Germline
    Hu Y; Alden RS; Odegaard JI; Fairclough SR; Chen R; Heng J; Feeney N; Nagy RJ; Shah J; Ulrich B; Gutierrez M; Lanman RB; Garber JE; Paweletz CP; Oxnard GR
    Clin Cancer Res; 2017 Dec; 23(23):7351-7359. PubMed ID: 28947568
    [No Abstract]   [Full Text] [Related]  

  • 37. Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA.
    Gawroński AR; Lin YY; McConeghy B; LeBihan S; Asghari H; Koçkan C; Orabi B; Adra N; Pili R; Collins CC; Sahinalp SC; Hach F
    Nucleic Acids Res; 2019 Apr; 47(7):e38. PubMed ID: 30759232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
    PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using plasma cell-free DNA to monitor the chemoradiotherapy course of cervical cancer.
    Tian J; Geng Y; Lv D; Li P; Cordova M; Liao Y; Tian X; Zhang X; Zhang Q; Zou K; Zhang Y; Zhang X; Li Y; Zhang J; Ma Z; Shao Y; Song L; Owen GI; Li T; Liu R; Liu Q; Zou L; Zhang Z; Li Z
    Int J Cancer; 2019 Nov; 145(9):2547-2557. PubMed ID: 30919951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer.
    Chan RH; Lin PC; Chen SH; Lin SC; Chen PC; Lin BW; Shen MR; Yeh YM
    Front Oncol; 2021; 11():589673. PubMed ID: 33816227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.